Intensive fundus screenings reduces need for enucleation

Article

Intensive fundus screening in retinoblastoma patients decreases the need for enucleation and external beam radiation (EBRT).

Intensive fundus screening in retinoblastoma patients decreases the need for enucleation and external beam radiation (EBRT), according to a study published in Eye.

The investigation, led by Dr P.R. Rothschild, Department of Ocular Oncology, Institut Curie, Paris, France, analysed the fundus examination results of 547 retinoblastoma patients between January 1995 and December 2004. Fundus exams were performed on children shortly after birth. All patients had a positive family history of retinoblastoma and underwent fundus screening under general anaesthesia.

Familial retinoblastoma cases were retrospectively placed into a 'screened' group and a 'non-screened' group (NS). The screened group were classified as intensively screened (IS) or non-intensively screened (NIS). The Fisher exact test was used to compare categorical variables between groups. The Kruskal-Wallis test was also used to compare continuous variables.

Of the 547 retinoblastoma patients included in the study, 59 were identified as familial cases. The NS group contained 20 patients, the S group consisted of 23 and the IS group had 16 patients.

The number of children who experienced enucleation was 13 for the NS group, 2 for the S group and 0 for the IS group. External beam radiation (EBRT) was completed in 6 of the NS children, 0 in the S group and 2 in the IS group.

Visual acuity and chemotherapy burden were not significantly different when compared between the groups. Intensive fundus screening reduced the need for enucleation and EBRT in children. The study recommends the referral of children with retinoblastoma for genetic counselling and sufficient fundus screening.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.